Parmax Pharma Limited has submitted a regulatory filing to the Bombay Stock Exchange Limited, Department of Corporate Services, Mumbai. The disclosure is made pursuant to Regulation 29 of the SEBI Listing Regulations, 2015.
The Board of Directors meeting is scheduled for Saturday, May 30, 2026. The primary agenda is to consider and approve the Audited Financial Results for both the quarter and the financial year ended March 31, 2026.
The company confirms that the trading window for dealing in the company's securities, which was communicated earlier, remains closed for all insiders. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) and the company's internal Code to Regulate, Monitor and Report Trading by Insiders. The trading window will reopen 48 hours after the official announcement of the audited financial results for the period ended March 31, 2026.
The letter is signed by Umang Alkesh Gosalia, Managing Director (DIN: 05153830), on behalf of Parmax Pharma Limited, requesting the exchange to take the information on record.